Hexapeptide-11

Hexapeptide-11 is a bioactive peptide derived from Saccharomyces cerevisiae (baker's yeast) fermentation. Unlike most cosmetic peptides that are fully synthetic, Hexapeptide-11 is produced through biotechnological extraction from yeast cultures, giving it a distinct origin and activity profile.

Overview

Epidermal renewal is a continuous process in which basal keratinocytes divide, differentiate, migrate upward through the epidermis, and are eventually shed from the skin surface as corneocytes. In young skin, this turnover cycle takes approximately 28 days. With aging, the cycle slows to 40-60 days, leading to accumulation of dull, rough surface cells, uneven pigmentation, and diminished barrier function. This slowdown reflects decreased mitotic activity in the basal layer.

Hexapeptide-11 addresses this age-related decline by directly stimulating keratinocyte proliferation. The peptide promotes entry into the S phase (DNA synthesis) of the cell cycle, increasing the rate at which basal cells divide and replenish the epidermis. This accelerated turnover mimics the effect of retinoids on epidermal renewal but through a peptide-mediated, non-irritating mechanism.

The yeast origin of Hexapeptide-11 connects it to the broader tradition of using Saccharomyces-derived ingredients in skincare. Yeast extracts, ferment lysates, and beta-glucans have long been used for their skin-conditioning properties. Hexapeptide-11 represents a more targeted, peptide-specific approach that isolates the bioactive renewal-stimulating component from the complex yeast metabolome.

Mechanism of Action

Hexapeptide-11 stimulates keratinocyte renewal through activation of cell cycle progression pathways. The peptide interacts with growth factor receptors on the surface of basal keratinocytes, triggering intracellular signaling cascades that promote transition from the G1 (gap 1) phase to the S (synthesis) phase of the cell cycle.

Key downstream effects include:

1. Cyclin-CDK activation -- the peptide upregulates cyclin D and cyclin E expression, which form complexes with cyclin-dependent kinases (CDK4/6 and CDK2) to phosphorylate the retinoblastoma protein (Rb) and release E2F transcription factors
2. DNA replication initiation -- released E2F factors activate genes required for DNA synthesis, driving cells into S phase
3. Increased mitotic rate -- accelerated cell cycling in the basal layer increases the production of new keratinocytes
4. Enhanced differentiation cascade -- newly produced keratinocytes enter the normal differentiation program, progressing through the spinous, granular, and cornified layers

The net effect is a faster epidermal turnover rate that replaces aged, UV-damaged surface cells with fresh keratinocytes. This produces measurable improvements in skin smoothness, luminosity, and evenness. Unlike chemical exfoliants (AHAs, BHAs) that remove surface cells from the outside, Hexapeptide-11 works from the inside by increasing the supply of new cells.

Reconstitution Calculator

Research

Safety Profile

Hexapeptide-11 has a favorable safety profile for topical cosmetic use. While the peptide stimulates keratinocyte proliferation, this effect is limited to physiological acceleration of the normal cell cycle and does not involve transformation or uncontrolled growth -- proliferation remains within normal homeostatic bounds. Dermatological testing shows no irritation, sensitization, or phototoxicity at recommended use concentrations. The yeast-derived origin has not been associated with allergic reactions in clinical studies, though individuals with known yeast allergies should exercise caution. Systemic absorption from topical application is negligible. The peptide is compatible with sensitive skin formulations and suitable for daily use.

Pharmacokinetic Profile